VP16-213 and cyclophosphamide in non oat cell bronchogenic carcinoma

Thirty-two patients with by non oat cell bronchogenic carcinoma were admitted to a protocol including Cyclophosphamide (CTX) 1,000 mg/m2 i.v. day 1, VP16-213 200 mg/m2 p.o. day 1–3, every 3 weeks.